A joint statement has been issued by the British Menopause Society, the International Menopause Society, the European Menopause and Andropause Society, the Royal College of Obstetricians and Gynaecologists and the Australasian Menopause Society on menopausal hormone therapy (MHT) and breast cancer risk in response to EMA Pharmacovigilance Risk Assessment Committee recommendations in May 2020.

Download Response to EMA Pharmacovigilance Risk Assessment Committee recommendations – May 2020 (PDF, 584KB)